研究業績

論文・出版

2017年


医師主導治験の実施体制整備状況と課題について:乳癌診療施設に対するアンケート調査(JBCRG-Q06)


JBCRG-Q06 坂東裕子、笠井宏委、青儀健二郎、大谷彰一郎、津川浩一郎、森岡由香、山口ひとみ、吉波哲大、橋本郁子、相馬道郎、戸井雅和、増田慎三、大野真司


乳癌の臨床 Vol.32 No. 6 2017 p477-483

JBCRGのあらたな取り組み -JCBRGの設立と経緯および臨床試験への取り組み


大野真司


医学のあゆみ Vol.261, No.5, page 572-576, 2017

Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)


H Kawaguchi, N Masuda, T Nakayama, K Aogi, K Anan, Y Ito, S Ohtani, N Sato, S Saji, E Tokunaga, S Nakamura, Y Hasegawa, M Hattori, T Fujisawa, S Morita, M Yamaguchi, T Yamashita, Y Yamamoto, S Ohno, and M Toi.


Breast Cancer Research and Treatment 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

アンケート調査からみる医師主導治験の課題と展望


笠井宏委、坂東裕子、青儀健二郎、大野真司


CANCER BOARD of the BREAST Vol.3 No.2 p52-53(116-117) 乳癌カレントトピックス、 2017

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno


CURRENT MEDICAL RESEARCH AND OPINION, 2017

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)


Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi


Cancer Medicine, open access, 2017

任意団体JBCRG 研究業績